| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44050523 | HTLV-1 | ENSG00000232810.5 | protein_coding | TNF | No | No | 7124 | P01375 Q5STB3 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | TNF |
|---|---|
| DrugBank ID | DB00051 |
| Drug Name | Adalimumab |
| Target ID | BE0000704 |
| UniProt ID | P01375 |
| Regulation Type | inhibitor |
| PubMed IDs | 12044041; 14532145; 15022409; 15046527; 31075754 |
| Citations | Lorenz HM: Technology evaluation: adalimumab, Abbott laboratories. Curr Opin Mol Ther. 2002 Apr;4(2):185-90.@@Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii30-3.@@Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M: [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies]. Rev Med Chil. 2003 Dec;131(12):1445-53.@@Bang LM, Keating GM: Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121-39.@@Matusiak L, Jemec GB, Szepietowski JC: Pharmacological development in hidradenitis suppurativa. Curr Opin Pharmacol. 2019 Jun;46:65-72. doi: 10.1016/j.coph.2019.04.006. Epub 2019 May 7. |
| Groups | Approved; Experimental |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | PA10004 |
| ChEMBL | CHEMBL1201580 |
